Thermo Fisher Q4 revenue, profit beat estimates

Thermo Fisher Scientific

29/01/2026 11:08

Overview

Science services leader's Q4 revenue grew 7%, beating analyst expectations

Adjusted EPS for Q4 beat analyst expectations

Company completed acquisitions to enhance bioproduction and clinical trial capabilities

Outlook

Company will provide 2026 financial guidance during its earnings conference call

Result Drivers

INNOVATIVE PRODUCT LAUNCHES - Co launched new products like Helios MX1 Plasma Focused Ion Beam Scanning Electron Microscope, contributing to Q4 growth

STRATEGIC COLLABORATIONS - Co's collaboration with OpenAI and expansion of bioprocess design centers in Asia supported growth

CAPITAL DEPLOYMENT - Co's acquisition of Clario and other investments enhanced capabilities, driving Q4 results

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q4 Revenue
Beat
$12.22 bln
$11.95 bln (18 Analysts)
Q4 Adjusted EPS
Beat
$6.57
$6.45 (20 Analysts)
Q4 EPS
$5.21
Q4 Adjusted Net Income
Beat
$2.48 bln
$2.43 bln (15 Analysts)

Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 25 "strong buy" or "buy", 4 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the advanced medical equipment & technology peer group is "buy"

Wall Street's median 12-month price target for Thermo Fisher Scientific Inc is $652.00, about 7.2% above its January 28 closing price of $608.02

The stock recently traded at 25 times the next 12-month earnings vs. a P/E of 20 three months ago

Press Release: ID:nBw1Q3rd4a

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)